RAPTOR

Multi-omics Startup Pleno Inc. Expands Leadership Team to Accelerate Development of its Novel Hypercoding Technology

Retrieved on: 
Wednesday, October 26, 2022
Health, Technology, Health Technology, Other Technology, Telecommunications, Clinical Trials, Biotechnology, University of California, San Diego, Doctor of Philosophy, Apple Inc., Telecommunication, Distinguishing, General manager, VP, Electrical engineering, Monolithic kernel, Indian Institute of Technology (BHU) Varanasi, Computer, Coronavirus Scientific Advisory Board (Turkey), RAPTOR, Biochemistry, GPS, National Academy of Engineering, Institute, Senior, Cancer, University, VC, Industry, Health, Wi-Fi, Broadcom Corporation, CTO, Electricity, Biomedical Research, Broadcom Inc., Wireless, IEEE, Inc., 3D printing, Management, Mobile phone, Technology, Engineering, Seshadri, Software, En Pleno Vuelo

We are incredibly excited to bolster our highly skilled team with the capabilities and experience that both Jason and Nambi bring to the table.

Key Points: 
  • We are incredibly excited to bolster our highly skilled team with the capabilities and experience that both Jason and Nambi bring to the table.
  • Pleno has had longstanding relationships with both of them, and were thrilled to be bringing them on in a larger capacity as we continue to expand.
  • Pleno is rapidly growing its San Diego, California-based team of experienced scientists, telecoms engineers, and biotechnology innovators developing its RAPTORTM instrument platform.
  • The companys proprietary Hypercoding technology leverages signal processing techniques from the telecommunications industry to deliver targeted biological information at unprecedented scale, precision, and performance.

InventHelp Inventor Develops Additional Vehicle Lighting (SGM-162)

Retrieved on: 
Wednesday, October 26, 2022
RAPTOR, Sale, Ninth Street, Eye, Multimedia, Weather, Publishing

"I thought of this idea to help give vehicle operators the ability to provide light in the drive they most need it."

Key Points: 
  • "I thought of this idea to help give vehicle operators the ability to provide light in the drive they most need it."
  • Additionally, this would help eliminate the need for periodic adjustments and reduces the need to remove front end vehicle components for all types of vehicle owners.
  • The original design was submitted to the Indianapolis sales office of InventHelp.
  • 21-SGM-162, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

InventHelp Presents Additional Vehicle Lighting (SGM-162)

Retrieved on: 
Tuesday, October 25, 2022
RAPTOR, Sale, Ninth Street, Eye, Multimedia, Weather

"I thought of this idea to help give vehicle operators the ability to provide light in the drive they most need it."

Key Points: 
  • "I thought of this idea to help give vehicle operators the ability to provide light in the drive they most need it."
  • Additionally, this would help eliminate the need for periodic adjustments and reduces the need to remove front end vehicle components for all types of vehicle owners.
  • The original design was submitted to the Indianapolis sales office of InventHelp.
  • 21-SGM-162, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Oncocross Begins Clinical Trial for AI-Developed Drug for Sarcopenia

Retrieved on: 
Friday, February 25, 2022
Oncology, Health, Technology, Other Technology, Clinical Trials, Pharmaceutical, Biotechnology, RAPTOR, Sarcopenia, Conditional sentence, Prognosis, Pharmacokinetics, International Classification of Diseases, Clinical trial, Drug development, Duchenne, Safety, Disease, Trial of the century, Cancer, Muscle, Biomarker, IND, ALS, Daewoong Pharmaceutical, Ageing, Patient, Quality of life, CEO, Duchenne muscular dystrophy, Medical device, Pharmaceutical industry

Oncocross , an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for OC514 targeting muscular diseases including sarcopenia.

Key Points: 
  • Oncocross , an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for OC514 targeting muscular diseases including sarcopenia.
  • Sarcopenia is a disease characterized by progressive loss of skeletal muscle mass and strength, thereby deteriorating normal physical function.
  • Upon completion of phase I, Oncocross plans to conduct phase II clinical trials for OC514, targeting cancer patients accompanying sarcopenia.
  • OC514 has a significant meaning for us since it is one of the first AI-driven drug candidates for sarcopenia that is going into clinical trials globally.

Turnstone Biologics Expands Scientific Advisory Board with Appointments of Dr. James Mulé and Dr. Eric Tran

Retrieved on: 
Wednesday, December 15, 2021
Oncology, Health, General Health, Research, Science, Biotechnology, American Association, Adoptive cell transfer, Technology, Research, United States Air Force Scientific Advisory Board, SAB, Company, University of Washington Department of Bioengineering, Cancer, Secondary research, Clinical trial, Melanoma, H. Lee Moffitt Cancer Center & Research Institute, RAPTOR, Earle, American Association for Cancer Research, National, University of Victoria, Melanoma Research, Immunotherapy, Michael, Association, Patient, Therapy, Science, Leadership, Fred Hutchinson Cancer Research Center, TILS, TIL, University, Potyvirus, DRS, Takeda, Division, Treatment, Antigen, National Cancer Institute, Senior, Immunology, Pharmaceutical industry, Medical imaging, Vaccine, Turnstone

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leaders in the cell therapy field, James Mul, IPh.D., and Eric Tran, Ph.D.

Key Points: 
  • Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leaders in the cell therapy field, James Mul, IPh.D., and Eric Tran, Ph.D.
  • Mul and Tran, with their unparalleled expertise in the fields of cancer immunotherapy and cell therapy, join the Turnstone SAB at this exciting time for the Company, said Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone.
  • I am thrilled to support Turnstone as the Company prepares to progress its novel TIL technology into the clinic and beyond, said Dr. Mul.
  • Dr. Eric Tran leads the Adoptive Cell Therapy Laboratory at Earle A. Chiles Research Institute, a division of Providence Cancer Institute.

Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications

Retrieved on: 
Monday, November 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, RAPTOR, CEO, American Nurses Credentialing Center, Turnstone, Company, TIL, Partnership, Cancer, MBA, IND, Breast, Education, National Cancer Institute, Takeda, Therapy, Melanoma, Nursing, Research, Investor, TILS, Roswell Park Comprehensive Cancer Center, Associate, H. Lee Moffitt Cancer Center & Research Institute, Moffitt, Pharmaceutical industry, Vaccine, Turnstone Biologics, Moffitt Cancer Center, TURNSTONE BIOLOGICS, MOFFITT CANCER CENTER

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center (Moffitt) for pre-clinical development of investigational tumor-infiltrating lymphocyte (TIL) therapies.

Key Points: 
  • Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center (Moffitt) for pre-clinical development of investigational tumor-infiltrating lymphocyte (TIL) therapies.
  • We look forward to working closely with the team at Moffitt as we advance our innovative strategy in this field.
  • Furthermore, Turnstone will transfer their proprietary TIL manufacturing process to Moffitt to produce cell products for upcoming clinical studies of Turnstones TIL product candidates.
  • Turnstone aims to drive clinical efficacy in harder to treat, lower mutational burden cancer indications with its TIL platform.

Axalta unveils fresh paint scheme for Hendrick Motorsports' No. 24 car to showcase new brand RAPTOR®

Retrieved on: 
Tuesday, October 19, 2021
Acquisition, Chevrolet, Steel, Kansas Speedway, NAPA, Technology, Twitter, Paint, Chevrolet Camaro, NYSE, Corrosion, Plastic, Grand Prix motorcycle racing, Senior, AutoZone, Formula One, Amazon, NASCAR, GLEN, RAPTOR, NASCAR Cup Series career of Jeff Gordon, Phoenix Raceway, Industry, Partnership, Solution, NASCAR Cup Series, IMSA, Color, Hendrick Motorsports, Wood, WEC

GLEN MILLS, Pa., Oct. 19, 2021 /PRNewswire/ -- Axalta (NYSE: AXTA), a leading global supplier of liquid and powder coatings, today unveiled a brand-new paint scheme for Hendrick Motorsports' iconic No. 24 Chevrolet Camaro ZL1 1LE that spotlights Axalta's newest acquisition, U-POL, and its RAPTOR® brand. William Byron will race the eye-catching design – featuring a rugged charcoal base with striking, bright green accents – at the NASCAR Cup Series races at Kansas Speedway on Oct. 24 and in the season finale at Phoenix Raceway on Nov. 7.

Key Points: 
  • GLEN MILLS, Pa., Oct. 19, 2021 /PRNewswire/ --Axalta (NYSE: AXTA), a leading global supplier of liquid and powder coatings, today unveiled a brand-new paint scheme for Hendrick Motorsports' iconic No.
  • Axalta completed its acquisition of U-POL, a leading supplier of paint, protective coatings and accessories primarily for the automotive aftermarket, in September.
  • The new paint scheme will look great on track and we hope to see it in victory lane."
  • Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions.

Fred VanVleet Joins UTU.ONE

Retrieved on: 
Friday, July 16, 2021
Maple Leaf Sports & Entertainment, Toronto Raptors, National Basketball Association, RAPTOR, Basketball

The move also opens the door to the massive global sports and collectable market.

Key Points: 
  • The move also opens the door to the massive global sports and collectable market.
  • Equipped with an indomitable spirit and self-belief, Fred signed with the Toronto Raptors, spending time with the Raptors 905 to hone his game and was a key member of the Raptors 905 championship team, leading in to Fred starring for the Toronto Raptors and their 2019 NBA Championship team where Fred was one of the most clutch and important players.
  • The UTU.ONE App is currently in an open beta test and can be downloaded from both Apple and Google stores.
  • In 2020, UTU technology Inc. made the strategic decision to establish its HQ in Toronto, Canada to further the company's business expansions worldwide.

Raptor Maps Announces Madison Energy Investments as SaaS Launch Partner to Maximize Asset Performance

Retrieved on: 
Thursday, June 24, 2021
Software, Other Energy, Utilities, Alternative energy, Energy, Other Construction & Property, Technology, Commercial Building & Real Estate, Environment, Construction & Property, Building Systems, Other Technology, Rocket engines, SpaceX Raptor, RAPTOR, Rocket propulsion, Engines, Madison Energy Investments, Raptor Maps, MADISON ENERGY INVESTMENTS, RAPTOR MAPS

Raptor Maps, the leading software startup in C&I and utility-scale solar, announced Madison Energy Investments as its newest launch partner.

Key Points: 
  • Raptor Maps, the leading software startup in C&I and utility-scale solar, announced Madison Energy Investments as its newest launch partner.
  • The companys latest software-as-a-service (SaaS) offering equips Madison Energy Investments with the digital tools needed to maximize the performance of its fast-growing Commercial and Industrial (C&I) portfolio.
  • (Photo: Business Wire)
    Madison Energy Investments is serious about asset performance, explains Jack Hachmann, Managing Partner at Madison Energy Investments.
  • Raptor Maps is proud to power the most innovative companies in solar, notes Nikhil Vadhavkar, CEO of Raptor Maps.

Florida School Districts Select Raptor Technologies as their Panic Alert Solution for Alyssa's Law Requirement

Retrieved on: 
Thursday, June 24, 2021
Rocket engines, SpaceX Raptor, RAPTOR, RAPTOR, Joni Anwar, Gadsden, Rocket propulsion, Engines

HOUSTON, June 24, 2021 /PRNewswire/ --Raptor Technologies, the leading provider of school safety software, has been selected by seven Florida counties as the mobile panic alert provider to meet the Alyssa's Law requirement for the upcoming 2021-2022 school year.

Key Points: 
  • HOUSTON, June 24, 2021 /PRNewswire/ --Raptor Technologies, the leading provider of school safety software, has been selected by seven Florida counties as the mobile panic alert provider to meet the Alyssa's Law requirement for the upcoming 2021-2022 school year.
  • The Polk, Sarasota, Charlotte, Nassau, Gadsden, Holmes, and Bradford County school districts have selected Raptor to provide a mobile panic alert system connecting school staff directly to first responders.
  • The Florida Department of Education selected Raptor Technologies' mobile panic alert, Raptor Alert, as one of the approved solutions for school districts to implement before the August 2021 deadline, as required by the Alyssa's Law mandate.
  • Florida school districts have the option of selecting Raptor directly, or through Raptor's relationship with AT&T and Mutualink.